Resource Library

Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.

  • Programs & Targets

  • Indications

  • Year

  • Resource Type/Format

  • Development Stage

Related Resources

June 14, 2024

Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Hematologic and Solid Tumor Cancers

European Hematology Association (EHA) 2024
cHL CTCL Liquid Tumors Solid Tumors
Read More
April 7, 2024

E3 Pairing and Structural Mechanisms Underlying Anti-Tumor Activity of Clinical STAT3 Degrader KT-333

American Association for Cancer Research (AACR) 2024 Annual Meeting
Read More
December 10, 2023

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

American Society of Hematology (ASH) Annual Meeting and Exposition 2024
CTCL LGL-L PTCL Solid Tumors
Read More
June 14, 2023

Phase 1 trial of KT-333, a STAT3 degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia and solid tumors

International Conference on Malignant Lymphoma (ICML) 2023
CTCL LGL-L PTCL Solid Tumors
Read More
December 12, 2022

Leveraging Pre-Clinical Animal Model of CTCL to Explore Therapeutic Potential of a Novel STAT3 Degrader

American Society of Hematology Annual Meeting and Expo
CTCL
Read More
October 19, 2022

KT-333, A First-in-Class STAT3 Degrader, Caused Strong STAT3 Degradation and Consistent Downstream Biology In Vitro and In Vivo

20th Annual Discovery on Target Conference
Liquid Tumors Solid Tumors
Read More
June 1, 2022

Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
CTCL LGL-L PTCL Solid Tumors
Read More
December 13, 2021

Selective STAT3 Degraders Dissect Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens

The 63rd Annual ASH Meeting and Exposition
Liquid Tumors
Read More
December 13, 2021

A First-in-Class STAT3 Degrader KT-333 in Development for Treatment of Hematologic Cancers

The 63rd Annual ASH Meeting and Exposition
Liquid Tumors
Read More
November 12, 2021

Targeted STAT3 Degradation Leads to Remodeling of an Immunosuppressive Tumor Microenvironment and Subsequent Sensitization to Immune Checkpoint Inhibition

SITC 2021
Liquid Tumors Solid Tumors
Read More